LIVE
REGN
Regeneron Pharmaceuticals, Inc. · Healthcare
$609.94
-3.23% this month
VERSUS
⟷
COMPARE
BIIB
Biogen Inc. · Healthcare
$196.58
+3.16% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
REGN
3
BIIB
2
Comparison scoreboard
REGN LEADS 3/5AI Score
REGN ✓42.1
BIIB 28.5
1Y Return
REGN +19.86%
BIIB ✓+55.33%
Fwd P/E
REGN ✓11.34
BIIB 11.82
Target Up.
REGN ✓+36.62%
BIIB +12.04%
Op. Margin
REGN 20.66%
BIIB ✓22.90%
Metrics last refreshed: 6/22/2026
Quick take
REGN vs BIIB Stock Comparison: AI Score, Valuation, Performance and Upside
Regeneron and Biogen are both innovative biopharma companies with flagship products, but their risk profiles are sharply different. REGN's Dupixent is a proven, rapidly growing blockbuster with multiple expanding indications providing near-term earnings visibility. BIIB's Leqembi is a pioneering Alzheimer's drug but faces significant commercial challenges that have made its ramp much slower than anticipated.
Investors must choose between Regeneron's high-quality, high-multiple growth driven by Dupixent's proven commercial success versus Biogen's lower-multiple value proposition dependent on Leqembi proving it can overcome commercialization barriers at scale.
Live analysis · updated 6/22/2026
REGN holds the edge across 3 of 5 key metrics in this comparison. BIIB has delivered stronger 1-year price return (+55.33% vs +19.86%), though REGN trades at the lower forward P/E (11.34x vs 11.82x). On fundamentals, REGN is growing revenue faster (19.00%), while BIIB maintains the higher operating margin (22.90%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for REGN (+36.62%) than for BIIB (+12.04%).
Normalized 1Y performance
REGN
BIIB
Recent returns
REGN
BIIB
Analyst price targets & sentiment
REGN · 23 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.7/5.0)
Price target range
analyst low$535.00
analyst high$950.00
analyst mean$833.31
current price$609.94
+36.6% upside to analyst mean
BIIB · 31 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.2/5.0)
Price target range
analyst low$115.00
analyst high$260.00
analyst mean$220.25
current price$196.58
+12.0% upside to analyst mean
Who should consider this stock?
REGN may suit investors who:
- →want high-quality biopharma growth anchored by Dupixent's expanding multi-indication platform
- →value proprietary antibody discovery technology providing durable pipeline optionality
- →prefer companies with strong balance sheets and consistent earnings growth
- →are comfortable with premium valuation for superior pipeline visibility
BIIB may suit investors who:
- →believe Leqembi's Alzheimer's market will overcome payer and access barriers over time
- →see deep-value potential in a neuroscience leader trading at a discount to intrinsic value
- →want exposure to a potential breakthrough Alzheimer's franchise at an early commercial stage
- →are comfortable with higher uncertainty and longer timelines for the thesis to play out
Performance & AI score
| Metric | REGN | BIIB |
|---|---|---|
| AI score | 42.1 | 28.5 |
| AI rank | #882 | #2417 |
| Latest close | $609.94 | $196.58 |
| 1M return | -3.23% | +3.16% |
| 6M return | -18.65% | +14.22% |
| 1Y return | +19.86% | +55.33% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | REGN | BIIB |
|---|---|---|
| 1Y ago | $11.88K (+18.8%) started 2025-06-18 | $15.54K (+55.4%) started 2025-06-18 |
| 5Y ago | $11.46K (+14.6%) started 2021-06-21 | $5.16K (-48.4%) started 2021-06-21 |
| 10Y ago | $17.37K (+73.7%) started 2016-06-20 | $8.28K (-17.2%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | REGN | BIIB |
|---|---|---|
| Market cap | $63.95B | $29.02B |
| Trailing P/E | 14.88 | 21.14 |
| Forward P/E | 11.34 | 11.82 |
| Price/Sales | 3.78 | 1.99 |
| EV/Revenue | 3.75 | 3.15 |
| Analyst target | $833.31 | $220.25 |
| Target upside | +36.62% | +12.04% |
Growth, profitability & risk
| Metric | REGN | BIIB |
|---|---|---|
| Revenue growth | 19.00% | 1.90% |
| Earnings growth | -7.20% | 31.10% |
| EPS growth | -7.20% | +31.10% |
| FCF margin | +21.94% | +19.43% |
| Operating margin | 20.66% | 22.90% |
| Profit margin | 29.65% | 13.80% |
| ROIC proxy | 14.55% | 7.70% |
| Return on equity | 14.55% | 7.70% |
| Dividend yield | 0.62% | N/A |
| Beta | 0.24 | 0.18 |
| Debt/equity | 8.61 | 35.18 |
| Current ratio | 3.56 | 3.06 |
| Quick ratio | 2.84 | 2.02 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
REGN max drawdown26.05%
BIIB max drawdown14.34%
REGN max wkly drop12.87%
BIIB max wkly drop12.37%
5Y risk snapshot
REGN max drawdown59.69%
BIIB max drawdown70.23%
REGN max wkly drop20.21%
BIIB max wkly drop13.62%
10Y risk snapshot
REGN max drawdown59.69%
BIIB max drawdown72.66%
REGN max wkly drop20.21%
BIIB max wkly drop34.30%
Performance metrics by period
| Period | Metric | REGN | BIIB |
|---|---|---|---|
| 1Y | Growth | +18.76% | +55.35% |
| CAGR | +18.79% | +55.45% | |
| Sharpe ratio | 0.55 | 1.36 | |
| Max drawdown | 26.05% | 14.34% | |
| Max daily drop | 9.82% | 6.43% | |
| Max wkly drop | 12.87% | 12.37% | |
| 5Y | Growth | +14.48% | -48.39% |
| CAGR | +2.75% | -12.41% | |
| Sharpe ratio | 0.10 | -0.36 | |
| Max drawdown | 59.69% | 70.23% | |
| Max daily drop | 19.01% | 7.39% | |
| Max wkly drop | 20.21% | 13.62% | |
| 10Y | Growth | +73.43% | -17.19% |
| CAGR | +5.66% | -1.87% | |
| Sharpe ratio | 0.19 | 0.04 | |
| Max drawdown | 59.69% | 72.66% | |
| Max daily drop | 19.01% | 29.23% | |
| Max wkly drop | 20.21% | 34.30% |
Business comparison
| Category | REGN | BIIB |
|---|---|---|
| Company | Regeneron Pharmaceuticals, Inc. | Biogen Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Core business | Regeneron is a science-driven biopharmaceutical company with a technology platform (Veloci-Suite) that enables rapid antibody discovery. Its commercial portfolio is anchored by Dupixent (dupilumab) for atopic dermatitis and other Th2-driven inflammatory diseases, growing at 25%+ annually with multiple ongoing label expansions. Eylea (aflibercept) for eye diseases provides a second major revenue stream, though facing biosimilar competition from Eylea HD (its own successor product). REGN-EB3 for Ebola and odronextamab in lymphoma represent additional pipeline assets. | Biogen pioneered the treatment of multiple sclerosis and remains a leader in MS with drugs including Tecfidera (now generic), Tysabri, and Vumerity. Its Alzheimer's franchise — lecanemab (Leqembi, developed with Eisai) — represents the company's highest-stakes pipeline bet, as one of the first amyloid-clearing drugs to show clinical benefit. Biogen also has biosimilars revenue and a neuroscience portfolio including Skyclarys for Friedreich's ataxia. |
| Investor focus | Investors focus on Dupixent's expanding indications (COPD, prurigo nodularis, and others), the Eylea to Eylea HD transition success, and the depth of the broader pipeline beyond these two anchors. | Investors track Leqembi's commercial uptake (slowed by payer coverage and infusion logistics challenges), MS product revenue retention against generic competition, and whether the broader neuroscience pipeline can provide a sustainable revenue growth bridge. |
REGN strengths
- →Dupixent is one of the fastest-growing large-molecule drugs globally with 10+ approved indications
- →Veloci-Suite antibody discovery platform provides ongoing pipeline generation advantage
- →Strong balance sheet with significant cash enabling pipeline investment and buybacks
BIIB strengths
- →Leqembi (lecanemab) is one of the first approved Alzheimer's disease-modifying treatments
- →Deep neuroscience expertise and relationships spanning 40+ years of MS drug development
- →Eisai partnership on Leqembi shares development costs and commercialization risk
Risks to watch — REGN
- →Eylea biosimilar competition creating headwinds for the legacy eye care franchise
- →Dupixent growth will eventually slow as market penetration matures in lead indications
- →High dependence on two products (Dupixent and Eylea) for the majority of revenue
Risks to watch — BIIB
- →Leqembi commercial uptake materially below initial projections due to payer and logistical hurdles
- →MS revenue base eroding from generic Tecfidera competition
- →Alzheimer's drug market may take years to scale, creating a prolonged revenue gap
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →